Insulin inhalation - MannKind Corporation

Drug Profile

Insulin inhalation - MannKind Corporation

Alternative Names: Afrezza; Technosphere® Insulin

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator MannKind Corporation
  • Developer MannKind Corporation; Sanofi
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 12 Jun 2016 Pharmacodynamics data from a phase I trial in Type-1 diabetes presented at the 76th Annual Scientific Sessions of the American Diabetes Association (ADA - 2016)
  • 10 Jun 2016 MannKind and JDRF agree to co-develop inhaled insulin for Type-1 diabetes in paediatric population
  • 14 Mar 2016 Suspended - Phase-I for Type-1 diabetes mellitus (In adolescents, In children) in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top